Publication:
Effectiveness of CoronaVac in children 3–5 years of age during the SARS-CoV-2 Omicron outbreak in Chile

Simple item page
dc.contributor.authorJara, Alejandro
dc.contributor.authorUndurraga, Eduardo A.
dc.contributor.authorZubizarreta, José R.
dc.contributor.authorGonzález, Cecilia
dc.contributor.authorAcevedo, Johanna
dc.contributor.authorPizarro, Alejandra
dc.contributor.authorVergara, Verónica
dc.contributor.authorSoto-Marchant, Mario
dc.contributor.authorGilabert, Rosario
dc.contributor.authorFlores, Juan Carlos
dc.contributor.authorSuárez, Pamela
dc.contributor.authorLeighton, Paulina
dc.contributor.authorEguiguren, Pablo
dc.contributor.authorRíos, Juan Carlos
dc.contributor.authorFernández, Jorge
dc.contributor.authorGarcía-Escorza, Heriberto
dc.contributor.authorAraos, Rafael
dc.date.accessioned2023-07-10T21:03:58Z
dc.date.available2023-07-10T21:03:58Z
dc.date.issued2022
dc.description.abstractThe outbreak of the B.1.1.529 lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Omicron) has caused an unprecedented number of Coronavirus Disease 2019 (COVID-19) cases, including pediatric hospital admissions. Policymakers urgently need evidence of vaccine effectiveness in children to balance the costs and benefits of vaccination campaigns, but, to date, the evidence is sparse. Leveraging a population-based cohort in Chile of 490,694 children aged 3–5 years, we estimated the effectiveness of administering a two-dose schedule, 28 days apart, of Sinovac’s inactivated SARS-CoV-2 vaccine (CoronaVac). We used inverse probability-weighted survival regression models to estimate hazard ratios of symptomatic COVID-19, hospitalization and admission to an intensive care unit (ICU) for children with complete immunization over non-vaccination, accounting for time-varying vaccination exposure and relevant confounders. The study was conducted between 6 December 2021 and 26 February 2022, during the Omicron outbreak in Chile. The estimated vaccine effectiveness was 38.2% (95% confidence interval (CI), 36.5–39.9) against symptomatic COVID-19, 64.6% (95% CI, 49.6–75.2) against hospitalization and 69.0% (95% CI, 18.6–88.2) against ICU admission. The effectiveness against symptomatic COVID-19 was modest; however, protection against severe disease was high. These results support vaccination of children aged 3–5 years to prevent severe illness and associated complications and highlight the importance of maintaining layered protections against SARS-CoV-2 infection.
dc.description.versionVersión publicada
dc.identifier.citationJara, A., Undurraga, E.A., Zubizarreta, J.R. et al. Effectiveness of CoronaVac in children 3–5 years of age during the SARS-CoV-2 Omicron outbreak in Chile. Nat Med 28, 1377–1380 (2022). https://doi.org/10.1038/s41591-022-01874-4
dc.identifier.doihttps://doi.org/10.1038/s41591-022-01874-4
dc.identifier.urihttps://repositorio.udd.cl/handle/11447/7683
dc.language.isoen
dc.subjectEpidemiology
dc.subjectViral infection
dc.titleEffectiveness of CoronaVac in children 3–5 years of age during the SARS-CoV-2 Omicron outbreak in Chile
dc.typeArticle
dcterms.accessRightsAcceso abierto
dcterms.sourceNature Medicine
dspace.entity.typePublication

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
s41591-022-01874-4 (1).pdf
Size:
3.78 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.63 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services